Iakovos Toumazis, Ph.D.
Department of Health Services Research, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | University of Buffalo, SUNY, Buffalo, NY, USA, PHD, Industrial Engineering |
| 2012 | University of Buffalo, SUNY, Buffalo, NY, USA, MS, Industrial Engineering |
| 2009 | University of Patras, Patras, GRC, BS, Mathematics |
Experience & Service
Consultantships
Expert Advisor, American Cancer Society, Atlanta, CA, 2021 - Present
Selected Publications
Peer-Reviewed Articles
- Toumazis I, Alagoz O, Leung A, Plevritis SK. A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer 127(23):4432-4446, 2021. e-Pub 2021. PMID: 34383299.
- Toumazis I, Erdogan SA, Bastani M, Leung A, Plevritis SK. A Cost-Effectiveness Analysis of Lung Cancer Screening with Low-Dose Computed Tomography and a Diagnostic Biomarker. JNCI Cancer Spectr 5(6), 2021. e-Pub 2021. PMID: 34738073.
- Toumazis I, de Nijs K, Cao P, Bastani M, Munshi V, Ten Haaf K, Jeon J, Gazelle GS, Feuer EJ, de Koning HJ, Meza R, Kong CY, Han SS, Plevritis SK. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol 7(12):1833-1842, 2021. e-Pub 2021. PMID: 34673885.
- Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas DE, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA 325(10):988-997, 2021. PMID: 33687469.
- Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. e-Pub 2021. PMID: 33536126.
- Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. Lung Cancer 147:154-186, 2020. e-Pub 2020. PMID: 32721652.
- Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. J Natl Cancer Inst 112(5):466-479, 2020. PMID: 31566216.
- Tammemägi MC, Ten Haaf K, Toumazis I, Kong CY, Han SS, Jeon J, Commins J, Riley T, Meza R. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial. JAMA Network Open 2(3):e190204. e-Pub 2019. PMID: 30821827.
- Toumazis I, Tsai EB, Erdogan SA, Han SS, Wan W, Leung A, Plevritis SK. Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. JNCI Cancer Spectrum 3(3):pkz035. e-Pub 2019. PMID: 31942534.
- Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Ann Intern Med 171(11):796-804. e-Pub 2019. PMID: 31683314.
- Han SS, Chow E, Ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemägi M, Jeon J, Feuer E, Meza R, Plevritis S. P1.11-03 Disparities and National Lung Cancer Screening Guidelines in the U.S. Population. Journal of Thoracic Oncology 14(10):S515-S516, 2019. PMID: 32040195.
- Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy & Practice 2(2):2381468317729650, 2017. e-Pub 2017. PMID: 30288431.
- Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes & Control 28(9):947-958. e-Pub 2017. PMID: 28702814.
- Toumazis I, Kwon C. Worst-Case Conditional Value-at-Risk Minimization for Hazardous Materials Transportation. Transportation Science 50 (4):1174 - 1187, 2016.
- Toumazis I, Kwon C. Routing Hazardous Materials on Time-Dependent Networks using Conditional Value-at-Risk. Transportation Research Part C: Emerging Technologies 37:73-92, 2013.
Abstracts
- Bastani M, Toumazis I, Plevritis SK, Hedou J, Leung A. MA05.09 Evaluation of Alternative Diagnostic Follow-Up Intervals for Lung-RADS Criteria on the Effectiveness of Lung Cancer Screening. Journal of Thoracic Oncology 16(3):S150-S151. e-Pub 2021.
- Han SS, Chow E, Ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemagi M, Jeon J, Feuer EJ, Meza R, Plevritis SK. Disparities of National Lung Cancer Screening Guidelines in the US Population. J Natl Cancer Inst 112(11):1136-1142, 2020. PMID: 32040195.
- Toumazis I, Alagoz O, Leung A, Plevritis SK. Individualized Risk-Based Lung Cancer Screening Incorporating Past Screening Findings and Changes in Smoking Behaviors. Journal of Thoracic Oncology 14(10)(S792), 2019.
- Toumazis I, Kurt M, Karacosta LG, Toumazi A, Kwon C, Goldstein DA. Assessing the role of sequencing up to three lines of chemotherapy in metastatic colorectal cancer treatment: A cost-effectiveness analysis. The 37th Annual Meeting of the Society of Medical Decision Making, St. Louis, MO, 2015.
- Toumazis I, Kurt M, Karacosta LG, Toumazi A, Kwon C, Goldstein DA. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. 2015 MSOM Healthcare Special Interest Group Meeting, Toronto, ON, 2015.
- Toumazis I, Kurt M, Ozaltin O, Denton BT, Shah ND. Eliciting cholesterol management guidelines' valuation of future life. The 36th Annual Meeting of the Society for Medical Decision Making, Miami, FL, 2014.
Book Chapters
- Toumazis I, Kwon C, Batta R. Value-at-risk and Conditional Value-at-Risk Minimization for Hazardous Materials Routing. In: Handbook of OR/MS Models in Hazardous Materials Transportation (Eds.: R. Batta and C. Kwon. Springer: New York, 2013.
Grant & Contract Support
| Title: | Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions |
| Funding Source: | Cancer Intervention and Surveillance Modeling Network (CISNET) |
| Role: | Co-Investigator |
| Title: | Understanding and Intercepting Ovarian Carcinogenesis” The BTC Minimal Original Disease (MOD) Ovarian Cancer Team |
| Funding Source: | Break Through Cancer (BTC) |
| Role: | Collaborator |
| Title: | Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Establishing the Value of Proton Therapy for Head and Neck Cancer: Assessing Cost-Effectiveness and Financial Toxicity of Therapy |
| Funding Source: | National Association for Proton Therapy (NAPT) |
| Role: | Co-Investigator |
| Title: | Development of a risk prediction and natural history models for ovarian cancer |
| Funding Source: | Duncan Family Institute for Cancer Prevention and Risk Assessment Seed-Funding Research Program |
| Role: | Principal Investigator |
| Title: | Smoking Cessation and Lung Cancer Screening for Dental Patients |
| Funding Source: | The University of Texas Health Science Center (UTHealth)-MD Anderson Cancer Center (MDACC) Population Health Initiative |
| Role: | Investigator |
| Title: | Lung Moon Shot Expanding Reach |
| Funding Source: | Moon Shot Program |
| Role: | Co-Leader |